

# [<sup>125</sup>I]-MARCROPHAGE INFLAMMATORY PROTEIN-1 $\alpha$ (HUMAN, RECOMBINANT) CCL3

Product Number: NEX298

## LOT SPECIFIC INFORMATION

CALCULATED AS OF: 12-Feb-2024

LOT NUMBER: GG31540

SPECIFIC ACTIVITY: 81.4 TBq/mmol  
2200 Ci/mmol  
10.2 MBq/ $\mu$ g  
275  $\mu$ Ci/ $\mu$ g

### Package Size Information

Package Size as of 15-Mar-2024
185 kBq 5 $\mu$ Ci
925 kBq 25 $\mu$ Ci

RADIOCHEMICAL PURITY:  $\geq$  95% by HPLC

MOLECULAR WEIGHT: ~8000

**PACKAGING:** [<sup>125</sup>I]-MIP-1 $\alpha$  is lyophilized from a solution containing 0.05M sodium acetate, 5% sucrose, 0.25% BSA, and a stabilizer, at pH 4.0-4.2. It is shipped ambient in a TPX3 vial.

**STABILITY AND STORAGE:** The lyophilized [<sup>125</sup>I]-MIP-1 $\alpha$  should be stored at 4°C or lower. Following reconstitution with distilled water to a concentration of approximately 25  $\mu$ Ci/ml on calibration date, aliquot and store at -20°C. Under these conditions the product is stable and usable in radioimmunoassays and receptor assays for at least six weeks after fresh lot date.

**SPECIAL INFORMATION:** [<sup>125</sup>I]-MIP-1 $\alpha$  sticks to glass. We recommend using plasticware or Sigma-Cote™ treated glassware to minimize this problem.

**SPECIFIC ACTIVITY:** The initial specific activity of [<sup>125</sup>I]-MIP-1 $\alpha$  is 2200 Ci/mmol (81 TBq/mmol), 275  $\mu$ Ci/ $\mu$ g (10 MBq/ $\mu$ g). Preparative HPLC separates unlabeled MIP-1 $\alpha$  from [<sup>125</sup>I]-MIP-1 $\alpha$ . Upon decay, [<sup>125</sup>I]-MIP-1 $\alpha$  undergoes decay catastrophe and the specific activity remains constant with time. However, it is not known what molecular fragments are generated from the decay event or what functional activity these fragments may have in different assays. References on <sup>125</sup>I decay and decay catastrophe of <sup>125</sup>I labeled compounds .

**PREPARATIVE PROCEDURE:** MIP-1 $\alpha$  (human, recombinant), obtained from PeproTech, Inc., Rocky Hill NJ, is radioiodinated with no carrier added <sup>125</sup>I using a lactoperoxidase procedure and is purified by reversed phase HPLC. This method predominantly labels tyrosine residues.

**AVAILABILITY:** [<sup>125</sup>I]-MIP-1 $\alpha$  is routinely available from stock and is prepared fresh and packaged for shipment on the second Monday of each month. Please inquire for larger package sizes.

**APPLICATIONS:** [<sup>125</sup>I]-MIP-1 $\alpha$  is useful in RIA, receptor studies and crosslinking experiments in the research into immune regulation.<sup>6-13</sup>

**HAZARD WARNING:** This product contains a chemical (s) known to the state of California to cause cancer. This product also contains a component which is harmful by contact, ingestion and inhalation. It is irritating to the eyes, skin and respiratory tract and is toxic.

**RADIATION UNSHIELDED:** 280mR/hr/mCi at vial surface.

**REFERENCES:**

1. Doyle, V.M., Buhler, F.R., Burgisser, E., *Eur. J. Pharm.* 99 353 (1984).
2. Schmidt, J., *J. Biol. Chem.* 259 1160 (1984).
3. Loring, R.H., Jones, S.W., Matthews-Bellinger, J., Salpeter, M.M., *J. Biol. Chem.* 257 1418 (1982).
4. Berridge, M.S., Jiang, V.W., Welch, M.J., *Rad. Res.* 82 467 (1980).
5. Charlton, D.E., *Rad. Res.* 107 163 (1986).
6. Schall, T.J., *Cytokine* 3 165 (1991).
7. Oppenheim, J.J., Zachariae, C.O.C., Mukaida, N., Matsushima, K., *Ann. Rev. Immunol.* 9 617-648 (1991).
8. Wolpe, S.D., Davatelis, D., Sherry, B., Butler, B., Hesse, D.J., Nguyen, H.T., Moldawer, L.L., Nathan, C.F., Lowry, S.F., Cerami, A., *J. Exp. Med.* 167 570 (1988).
9. Broxmeyer, H.E., Sherry, B., Cooper, S., Ruscetti, F.W., Williams, D.E., Arosio, P., Kwon, B.S., Cerami, A., *J. Immunol.* 147 2586 (1991).
10. Schall, T.J., O'Hehir, R.E., Goeddel, D.V., Lamb, J.R., *J. Immunol.* 148 381 (1992).
11. Wang, J.M., Sherry, B., Fivash, M.J., Kelvin, D.J., Oppenheim, J.J., *J. Immunol.* 150 3022 (1993).
12. Sherry, B., Tekamp-Olson, P., Gallegos, C., Bauer, D., Davatelis, D., Wolpe, S.D., Masiarz, F., Coit, D., Cerami, A., *J. Exp. Med.* 168 2251 (1988).
13. Davatelis, D., Tekamp-Olsen, P., Wolpe, S.D., Hermsen, K., Luedke, C., Gallegos, C., Coit, D., Merryweather, J., Cerami, A., *J. Exp. Med.* 167 1939 (1988).

**Radiations: Gamma 35.5 keV (7%) , X-ray K alpha 27 KeV (112%), K beta 31 keV (24%)**

DAYS	0	2	4	6	8	10	12	14	16	18
0	1.000	0.977	0.955	0.933	0.912	0.891	0.871	0.851	0.831	0.812
20	0.794	0.776	0.758	0.741	0.724	0.707	0.691	0.675	0.660	0.645
40	0.630	0.616	0.602	0.588	0.574	0.561	0.548	0.536	0.524	0.512
60	0.500	0.489	0.477	0.467	0.456	0.445	0.435	0.425	0.416	0.406
80	0.397	0.388	0.379	0.370	0.362	0.354	0.345	0.338	0.330	0.322
100	0.315	0.308	0.301	0.294	0.287	0.281	0.274	0.268	0.262	0.256
120	0.250	0.244	0.239	0.233	0.228	0.223	0.218	0.213	0.208	0.203

To obtain the correct radioactive concentration or amount for a date before the calibration date: divide by the decay factor corresponding to the number of days before the calibration date. To obtain the correct radioactive concentration or amount for a date after the calibration date: multiply by the decay factor corresponding to the number of days after the calibration date.

The information provided in this document is valid for the specified lot number and date of analysis. This information is for reference purposes only and does not constitute a warranty or guarantee of the product's suitability for any specific use. Revvity, Inc., its subsidiaries, and/or affiliates (collectively, "Revvity") do not assume any liability for any errors or damages arising from the use of this document or the product described herein. REVVITY EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, REGARDLESS OF WHETHER ORAL OR WRITTEN, EXPRESS OR IMPLIED, ALLEGEDLY ARISING FROM ANY USAGE OF ANY TRADE OR ANY COURSE OF DEALING, IN CONNECTION WITH THE USE OF INFORMATION CONTAINED HEREIN OR THE PRODUCT ITSELF.



Revvity, Inc.  
940 Winter Street  
Waltham, MA 02451 USA

(800) 762-4000  
www.revvity.com

For a complete listing of our global offices, visit [www.revvity.com](http://www.revvity.com)  
Copyright ©2023, Revvity, Inc. All rights reserved.